Award details

Discovery that a dual-action screen (genomic/non-genomic) identifies retinoic acid receptor ligands of highest neurotrophic potency

Reference	BB/P004806/1
Principal Investigator / Supervisor	Professor Peter McCaffery
Co-Investigators / Co-Supervisors	Dr Iain Greig, Professor Bettina Platt, Professor Andrew Whiting
Institution	University of Aberdeen
Department	Sch of Medicine, Medical Sci & Nutrition
Funding type	Research
Value (£)	201,822
Status	Completed
Type	Research Grant
Start date	16/01/2017
End date	31/12/2018
Duration	24 months

Abstract

unavailable

Summary

The number of people in the UK suffering from diseases that accelerate the deterioration of the brain has shown a dramatic increase in recent years, with our ageing population and increasing life expectancy; however, there is a desperate lack of effective drugs to treat these diseases, which include Alzheimer's and Parkinson's. The retinoic acid receptor is a promising protective target for these diseases; this neuroprotective action is activated when the receptor binds a small lipid called a retinoid. We have discovered a new means for designing and identifying retinoids that switch on the receptor in a way that best maximises its protective action. We will develop new retinoids for their capacity to treat the damaging changes associated with Alzheimer's. We will form a company which will further develop and evaluate these compounds, to the stage that they can be licensed to pharma and taken into clinical trials, for the treatment of Alzheimer's and other neurodegenerative diseases.

Committee	Not funded via Committee
Research Topics	Neuroscience and Behaviour, Pharmaceuticals
Research Priority	X – Research Priority information not available
Research Initiative	Follow-On Fund (FOF) [2004-2015]
Funding Scheme	X – not Funded via a specific Funding Scheme

I accept the terms and conditions of use (opens in new window)

export PDF file

back to list new search